loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Umeclidinium Bromide

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Umeclidinium Bromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 193,644Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GSK launches once daily, single inhaler-triple therapy for COPD patients
    GSK launches once daily, single inhaler-triple therapy for COPD patients

    26 Apr 2022

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gsk-launches-once-daily-single-inhaler-triple-therapy-for-copd-patients/articleshow/91095214.cms

    ECONOMICTIMES
    26 Apr 2022
    Share Share
    CHMP opinions: EMA refuses asthma label expansion for GSK’s COPD Ellipta
    CHMP opinions: EMA refuses asthma label expansion for GSK’s COPD Ellipta

    01 Mar 2021

    // Allie Nawrat PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/ema-gsk-trelegy-asthma-refusal/

    Allie Nawrat PHARMACEUTICAL-TECHNOLOGY
    01 Mar 2021
    Share Share
    FDA Approvals Roundup: Detectnet, Nityr, Trelegy Ellipta
    FDA Approvals Roundup: Detectnet, Nityr, Trelegy Ellipta

    16 Sep 2020

    // R. Matthews RAPS

    https://www.raps.org/news-and-articles/news-articles/2020/9/fda-approvals-roundup-detectnet-trelegy-ellipta-ni

    R. Matthews RAPS
    16 Sep 2020
    Share Share
    GSK books 19% sales growth for first quarter
    GSK books 19% sales growth for first quarter

    29 Apr 2020

    // Selina McKee PHARMATIMES

    http://www.pharmatimes.com/news/gsk_books_19_sales_growth_for_first_quarter_1339304

    Selina McKee PHARMATIMES
    29 Apr 2020
    Share Share
    GSK filing accepted by European Medicines Agency for Trelegy Ellipta
    GSK filing accepted by European Medicines Agency for Trelegy Ellipta

    27 Feb 2020

    // PRESS RELEASE

    https://www.gsk.com/en-gb/media/press-releases/gsk-filing-accepted-by-european-medicines-agency-for-trelegy-ellipta-use-in-adult-patients-with-asthma/

    PRESS RELEASE
    27 Feb 2020
    Share Share
    GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma
    GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma

    03 Oct 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20191002005525/en

    BUSINESSWIRE
    03 Oct 2019
    Share Share